KRAS: A Promising Therapeutic Target for Cancer Treatment
- PMID: 31486755
- DOI: 10.2174/1568026619666190905164144
KRAS: A Promising Therapeutic Target for Cancer Treatment
Abstract
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. Scientists have not successfully developed drugs that target KRAS, although efforts have been made last three decades. In this review, we highlight the emerging experimental strategies of impairing KRAS membrane localization and the direct targeting of KRAS. We also conclude the combinatorial therapies and RNA interference technology for the treatment of KRAS mutant cancers. Moreover, the virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Keywords: Cancer treatment; KRAS; Mutant cancers; Oncogene; Therapeutic target; Viral oncogene..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Targeting Mutant KRAS for Anticancer Therapy.Curr Top Med Chem. 2019;19(23):2098-2113. doi: 10.2174/1568026619666190902151307. Curr Top Med Chem. 2019. PMID: 31475898 Review.
-
Drug Discovery by Targeting Mutant KRAS.Curr Top Med Chem. 2019;19(23):2079-2080. doi: 10.2174/156802661923191113144238. Curr Top Med Chem. 2019. PMID: 31762422 No abstract available.
-
Targeting mutated GTPase KRAS in tumor therapies.Eur J Med Chem. 2021 Dec 15;226:113816. doi: 10.1016/j.ejmech.2021.113816. Epub 2021 Sep 4. Eur J Med Chem. 2021. PMID: 34520956 Review.
-
The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges.Curr Top Med Chem. 2019;19(23):2143-2157. doi: 10.2174/1568026619666190828162217. Curr Top Med Chem. 2019. PMID: 31456522 Review.
-
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.Cold Spring Harb Perspect Med. 2018 Aug 1;8(8):a031518. doi: 10.1101/cshperspect.a031518. Cold Spring Harb Perspect Med. 2018. PMID: 29101114 Free PMC article. Review.
Cited by
-
KRAS modulates immune infiltration levels and survival outcomes in patients with lung adenocarcinoma.Medicine (Baltimore). 2023 Dec 29;102(52):e36597. doi: 10.1097/MD.0000000000036597. Medicine (Baltimore). 2023. PMID: 38206735 Free PMC article.
-
Revealing KRas4b topology on the membrane surface.Biochem Biophys Res Commun. 2023 Oct 20;678:122-127. doi: 10.1016/j.bbrc.2023.08.035. Epub 2023 Aug 21. Biochem Biophys Res Commun. 2023. PMID: 37633182
-
Establishing the Role of Iridoids as Potential Kirsten Rat Sarcoma Viral Oncogene Homolog G12C Inhibitors Using Molecular Docking; Molecular Docking Simulation; Molecular Mechanics Poisson-Boltzmann Surface Area; Frontier Molecular Orbital Theory; Molecular Electrostatic Potential; and Absorption, Distribution, Metabolism, Excretion, and Toxicity Analysis.Molecules. 2023 Jun 28;28(13):5050. doi: 10.3390/molecules28135050. Molecules. 2023. PMID: 37446713 Free PMC article.
-
Switching G-quadruplex to parallel duplex by molecular rotor clustering.Nucleic Acids Res. 2022 Oct 14;50(18):10249-10263. doi: 10.1093/nar/gkac811. Nucleic Acids Res. 2022. PMID: 36130267 Free PMC article.
-
Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis.Proc Natl Acad Sci U S A. 2022 Jul 26;119(30):e2119048119. doi: 10.1073/pnas.2119048119. Epub 2022 Jul 18. Proc Natl Acad Sci U S A. 2022. PMID: 35858411 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
